--- title: "Valerio Therapeutics 宣佈成立 InVimmune，這是一家專注於開發差異化體內細胞治療方案的新公司" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/285037962.md" description: "Valerio Therapeutics 推出了 InVimmune，這是一家專注於開發針對腫瘤、纖維化和自身免疫疾病的差異化體內細胞治療方法的新公司。該項目旨在滿足腫瘤領域中迫切的醫療需求，利用 Valerio 的專有技術平台。InVimmune 將得到一個專門的腫瘤科學顧問委員會的支持，其中包括一些知名專家。該公司強調其創新的免疫重編程策略，並計劃提供更多關於其發展的更新" datetime: "2026-05-04T07:05:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285037962.md) - [en](https://longbridge.com/en/news/285037962.md) - [zh-HK](https://longbridge.com/zh-HK/news/285037962.md) --- # Valerio Therapeutics 宣佈成立 InVimmune，這是一家專注於開發差異化體內細胞治療方案的新公司 **Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches** Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the “**Company**”), today announces the launch of **InVimmune**, a new company dedicated to developing differentiated **in vivo cell therapy** approaches with potential applications across oncology, fibrosis, autoimmune diseases and additional indications. InVimmune’s first indication is in oncology, addressing an area of high unmet medical need. _“Through InVimmune, we are adding a new strategic pillar to Valerio and expanding the reach of our platform into in vivo cell therapy. Our differentiated approach has the potential to be applied across several therapeutic areas, including oncology, fibrosis and autoimmune diseases, with a first indication in oncology where unmet medical need remains high. We continue to strengthen our team and broaden the network of experts surrounding the Company to accelerate the development of our technologies and pipeline. We believe that the quality of our talent, combined with the exceptional scientific advisors supporting Valerio and InVimmune, provides a strong foundation to execute our strategy and deliver on our ambitions.” said Julien Miara, Chief Executive Officer of the Company._ InVimmune has been established to extend the reach of Valerio’s technology platforms into in vivo cell therapy through a novel immune reprogramming approach. InVimmune will leverage Valerio’s proprietary single-domain antibody platform together with targeted-delivery capabilities to develop differentiated programs across multiple therapeutic areas, with an initial focus on oncology. To support InVimmune’s first oncology program, Valerio has established a dedicated **Oncology Scientific Advisory Board**, chaired by **Professor Eric Vivier**. The Board also includes **Frederick Ramsdell, PhD**, 2025 Nobel Prize in Physiology or Medicine laureate and Chair of the Scientific Advisory Board at Sonoma Biotherapeutics; **Alan Korman, PhD**, Chief Scientific Officer and Board Member at BlueSphere Bio; **Matteo Iannacone, MD, PhD**, Director of the Division of Immunology, Transplantation and Infectious Diseases, Professor of Pathology, and Head of the Dynamics of Immune Responses laboratory at the San Raffaele Scientific Institute and University in Milan; and **François Romagné**, Former CSO of Innate pharma, Professor of Immunotechnology. In parallel, **Olivier Demaria**, **PhD**, will serve as **Chief Scientific Officer of both Valerio and InVimmune** and will also sit on InVimmune’s Oncology Scientific Advisory Board, ensuring scientific continuity and close alignment across both organizations. **Wael Jdey**, **PhD**, will be promoted to **Chief Technical Officer of Valerio.** Valerio Therapeutics will provide further updates on InVimmune’s development in due course. **Professor Eric Vivier, Chair of the Oncology Scientific Advisory Board, added: **“_InVimmune is built around an innovative concept with the potential to open new therapeutic avenues across multiple disease areas. By combining targeted delivery with a differentiated immune reprogramming approach, the company aims to advance novel in vivo cell therapy programs. Its first indication in oncology addresses a setting of high unmet medical need and is supported by a strong scientific foundation_.” \*\*\*\*\*\* **About Valerio Therapeutics** Valerio Therapeutics (FR0010095596 – ALVIO) is a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies. The Company is listed on Euronext Growth Paris. For more information: \[www.valeriotherapeutics.com\]. **About InVimmune** InVimmune is a company launched by Valerio Therapeutics to develop differentiated in vivo cell therapy approaches with potential applications across oncology, fibrosis and autoimmune diseases. The company is built around a novel therapeutic concept designed to reprogram the immune response in vivo. InVimmune leverages Valerio’s expertise in single-domain antibodies and targeted delivery. Its first indication is in oncology, addressing an area of high unmet medical need, and is supported by a dedicated Oncology Scientific Advisory Board and shared scientific leadership. **_Forward-Looking Statements_** _This press release contains certain forward-looking statements concerning Valerio Therapeutics and its activities. These forward-looking statements are based on assumptions that Valerio Therapeutics considers reasonable. However, there can be no assurance that such forward-looking statements will prove accurate, as they are subject to numerous risks, including those described in the 2025 annual financial report published on April 28, 2026 and available on Valerio Therapeutics’ website, as well as changes in economic conditions, financial markets and the markets in which Valerio Therapeutics operates._ _The forward-looking statements contained in this press release are also subject to risks that are not yet known to Valerio Therapeutics or that are not currently considered material by Valerio Therapeutics. The occurrence of all or part of such risks could cause Valerio Therapeutics’ actual results, financial position, performance or achievements to differ materially from these forward-looking statements._ _This press release and the information contained herein do not constitute an offer to sell or subscribe for, nor a solicitation of an offer to purchase or subscribe for, Valerio Therapeutics shares in any country. The distribution of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform themselves of, and comply with, any such local restrictions._ **Valerio Therapeutics** Investor Relations: \[ir@valeriotx.com | +33 (0) 1 45 58 95 10\] View source version on businesswire.com: https://www.businesswire.com/news/home/20260504760916/en/ ### 相關股票 - [NBSE.ESC.US](https://longbridge.com/zh-HK/quote/NBSE.ESC.US.md) - [TOVX.US](https://longbridge.com/zh-HK/quote/TOVX.US.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [IPHA.US](https://longbridge.com/zh-HK/quote/IPHA.US.md) ## 相關資訊與研究 - [巨生醫獲 SelectUSA 醫療科技組金牌 啟動美國 A 輪募資目標 1000 萬美元](https://longbridge.com/zh-HK/news/286905054.md) - [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md) - [復宏漢霖：注射用 HLX43 用於治療晚期非小細胞肺癌的國際多中心 2 期臨牀研究完成首例患者給藥](https://longbridge.com/zh-HK/news/287195179.md) - [Relay 藥物在治療罕見血管疾病方面顯示出早期的潛力](https://longbridge.com/zh-HK/news/287094432.md) - [Eton Pharmaceuticals 增加了一個 2026 年的新產品發佈，因為它獲得了 IMPAVIDO 在美國的銷售權](https://longbridge.com/zh-HK/news/287025596.md)